All In Biotech

Drug Trial Radar · NCT07021209

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jan 14, 2025

Primary completion

Jan 13, 2028

Study completion Jan 13, 2028

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
Collaborators
Tongji Hospital
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Conditions

  • Neurological Autoimmune Diseases

Interventions

  • GT719 InjectionBiological

    GT719 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adversed eventsTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.